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Abstract
Background: Supervised injection facilities (SIFs) are legally sanctioned environments for people to inject drugs
under medical supervision. SIFs currently operate in ten countries, but to date, no SIF has been opened in the USA.
In light of increasing overdose mortality in the USA, this study evaluated willingness to use a SIF among youth who
report non-medical prescription opioid (NMPO) use.
Methods: Between January 2015 and February 2016, youth with recent NMPO use were recruited to participate in
the Rhode Island Young Adult Prescription Drug Study (RAPiDS). We explored factors associated with willingness to
use a SIF among participants who had injected drugs or were at risk of initiating injection drug use (defined as
having a sex partner who injects drugs or having a close friend who injects).
Results: Among 54 eligible participants, the median age was 26 (IQR = 24–28), 70.4% were male, and 74.1% were
white. Among all participants, when asked if they would use a SIF, 63.0% answered “Yes”, 31.5% answered “No”, and 5.
6% were unsure. Among the 31 participants reporting injection drug use in the last six months, 27 (87.1%) reported
willingness to use a SIF; 15 of the 19 (78.9%) who injected less than daily reported willingness, while all 12 (100.0%) of
the participants who injected daily reported willingness. Compared to participants who were unwilling or were unsure,
participants willing to use a SIF were also more likely to have been homeless in the last six months, have accidentally
overdosed, have used heroin, have used fentanyl non-medically, and typically use prescription opioids alone.
Conclusions: Among young adults who use prescription opioids non-medically and inject drugs or are at risk of initiating
injection drug use, more than six in ten reported willingness to use a SIF. Established risk factors for overdose, including
homelessness, history of overdose, daily injection drug use, heroin use, and fentanyl misuse, were associated with higher
SIF acceptability, indicating that young people at the highest risk of overdose might ultimately be the same individuals to
use the facility. Supervised injection facilities merit consideration to reduce overdose mortality in the USA.
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Background
Important public health and public safety concerns arise
from injection drug use, including HIV transmission [1],
hepatitis C virus (HCV) transmission [2, 3], overdose [3, 4],
abscesses and infections [5, 6], and improperly discarded
syringes [7]. Supervised injection facilities (SIFs)—also
called drug consumption rooms (DCRs), safe injection sites
(SISs), and medically supervised injection centers (MSIC-
s)—have attempted to address these concerns by providing
legally sanctioned, safer environments for people to inject
pre-obtained drugs under medical supervision [8]. To date,
more than 90 SIFs operate in ten countries (Australia,
Canada, Denmark, France, Germany, Luxembourg, The
Netherlands, Norway, Spain, and Switzerland) [9, 10].
Although there are different SIF models, facilities typically
aim to provide clean injection equipment, education for
safer injecting, medical response in the event of an over-
dose, and treatment referrals [8]. Many facilities offer a
comprehensive array of health and social services, including
detoxification and other substance use treatment services,
medical care, counseling, and legal assistance [11, 12].
Over the last decade, the public health impacts of SIFs
have been researched extensively. SIFs have been associ-
ated with reductions in overdose mortality [13], syringe
sharing [14], unsafe injection practices [15], public injec-
tion drug use and public syringe disposal [16, 17], and
demand for ambulance services [18]. SIF implementa-
tion has also been associated with increased referral to
and uptake of detoxification and other substance use
treatment services [19, 20]. Studies suggest that SIFs are
cost-effective, potentially saving millions of dollars by
preventing new HIV and HCV cases and overdose
deaths [21–25], issues particularly relevant in the USA
in recent years due to HIV outbreaks and the overdose
crisis [26, 27]. A systematic review demonstrated that
SIFs were not found to increase injection drug use, drug
trafficking, or crime in surrounding environments [28].
Despite this body of scientific evidence, no SIFs have
been implemented in the USA, primarily as a result of a
complex set of national, state, and local policies and laws
that forbid such facilities, most notably the so-called
Crack House Statute of the federal Controlled Substances
Act, which makes it unlawful to “knowingly open, lease,
rent, use, or maintain any place, whether permanently or
temporarily, for the purpose of manufacturing, distribut-
ing, or using any controlled substance” [29].
The state of Rhode Island, a small state in the North-
east United States, has experienced a dramatic increase
in overdose deaths in the last decade, and now has one
of the highest per capita overdose mortality rates in the
country [30]. Particularly concerning is a surge in
overdose deaths in the last 3 years due to illicitly
manufactured fentanyl, a synthetic opioid that is 50–100
times more potent than morphine [31, 32]. Accidental
overdose and death can be more likely to occur if
individuals knowingly use fentanyl or unknowingly use
other substances that have been adulterated with fen-
tanyl [33]. A large proportion (47%) of overdose deaths
in Rhode Island was attributable to fentanyl in 2015, and
preliminary data from March to May of 2016 suggests
that this proportion has continued to increase [34]. In
Rhode Island, a wide array of stakeholders has collabo-
rated to facilitate community responses to the overdose
and fentanyl epidemic and to increase access to nalox-
one and to treatment and recovery services, but more
efforts are needed to prevent overdose morbidity and
mortality [35]. In general, while important successes
have been achieved in the drug policy reform and harm
reduction movements, drug policy in the USA has until
very recently been framed as having zero tolerance/ab-
stinence as the goal, with addiction largely treated as a
criminal justice issue instead of as a public health one
[36]. Despite the mounting evidence that harm reduc-
tion interventions such as syringe services programs are
highly effective at preventing an array of drug-related
harms, the implementation of many evidence-based pro-
grams, including SIFs, is non-existent or lacking in the
USA [36].
Researchers and community organizations often con-
duct assessments of the prevalence and correlates of will-
ingness to use a SIF to help provide a case for SIF
implementation. Various studies have reported a high
prevalence of willingness to use a SIF among people who
inject drugs (PWID), and a number of factors related to
willingness have been identified, including injecting in
public, daily injection drug use, frequency of heroin use,
ever experiencing an overdose, and familiarity with the
concept of a SIF [37–47]. Studies have also shown that,
once implemented, SIFs do indeed attract people at high
risk of overdose, including those who inject in public and
others at risk of blood-borne infection transmission
[48–50]. However, to the best of our knowledge, only one
peer-reviewed study has explored willingness to use a SIF
among a sample in the USA. A study published in 2010
recruited PWID in San Francisco, California, and reported
that 85% of participants reported willingness to use a SIF;
having injected in public and having injected speedballs
were associated with willingness [41]. In addition, to our
best knowledge, no study has explored willingness to use a
SIF in the context of the recent surge in fentanyl-
attributable overdose deaths in North America [32].
Willingness to use a SIF in Rhode Island should be studied
given its high per capita overdose mortality rate, its high
proportion of fentanyl-attributable overdose deaths, and
recent mobilization to respond to the overdose and opioid
epidemics in the state [30, 31, 33–35].
This analysis uses data from the Rhode Island Young
Adult Prescription Drug Study (RAPiDS), a pilot study
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that recruited youth aged 18 to 29 in Rhode Island who
reported non-medical prescription opioid (NMPO) use.
Between 2000 and 2014, the rates of death from pre-
scription opioid overdose in the USA nearly quadrupled
[51]. The RAPiDS study explored NMPO use among
young adults in Rhode Island to help inform overdose
prevention and other harm reduction interventions for
this vulnerable population. We aim to report the preva-
lence of willingness to use a SIF among young adults
who use prescription opioids non-medically. We also ex-
plore participant characteristics associated with higher
willingness to use a SIF.
Methods
Participants
Young-adult NMPO users were invited to participate in
RAPiDS between January 2015 and February 2016.
Participants were recruited through targeted canvassing
(e.g., bus advertisement, flyer), internet-based recruit-
ment (e.g., posting to online classifieds such as craigs-
list), and word of mouth. Eligibility criteria were (1)
currently living in Rhode Island, (2) between 18 and
29 years of age, (3) able to provide informed consent, (4)
able to speak and feel comfortable completing a survey
in English, and (5) report NMPO use in the past 30 days.
Research staff screened interested individuals, and if eli-
gible, participants completed an interviewer-administered
survey in a public location of their choosing or at the
Brown University School of Public Health. The survey
lasted about 45 min, after which participants were com-
pensated $25 USD. RAPiDS was approved by the Brown
University Institutional Review Board (Protocol Entitled:
RAPiDS: The Rhode Island Young Adult Prescription
Study (#1403001006)).
Questions about SIF willingness and acceptability were
added midway through the study period; thus, only 98 of
the 200 enrolled participants were asked these questions.
We sought to assess willingness to use a SIF among the
participants who inject drugs or are at risk of initiating
injection drug use, which we defined as having a sex
partner or close friend who injects drugs. We decided to
include participants who had not injected drugs but who
had a sex partner or close friend who injects drugs be-
cause previous research has shown these persons to have
a high risk of initiating injection drug use [52]. More-
over, exploring willingness to use a SIF among people at
risk of initiating injecting might be useful in terms of ga-
ging willingness to use a SIF among potential future in-
jectors, and due to the fact that some SIFs (i.e.,
supervised consumption facilities) permit non-injection
drug use [11, 53]. Thus, to be included in this analysis,
participants had to be asked questions about SIF willing-
ness and meet one or more of the following criteria: (1)
have ever injected drugs, (2) have a sex partner who
injects drugs, and (3) have at least one close friend who
injects drugs. Among the 98 participants who were
asked questions about SIF willingness, 34 participants
had ever injected drugs, and 20 of the participants who
had never injected drugs reported they had a sex partner
who injects drugs and/or had at least one close friend
who injects drugs. These 54 participants constitute the
sample of this analysis. The other 44 participants had
never injected drugs nor did they report having a sex
partner or close friend who injects drugs, so they were
excluded from the analytic sample. Thus, the total num-
ber of excluded participants was thus 146: 102 were not
asked questions about SIF willingness, and 44 were
asked questions about SIF willingness but had not
injected drugs and did not have a sex partner or close
friend who injects. In a supplementary analysis, we com-
pared the demographics of eligible participants with ex-
cluded participants (see Additional file 1).
Measures and statistical analyses
First, we ascertained whether participants would use a
SIF service if one were available. Participants were asked,
“If there was a legal service you could go to for free to
inject safely indoors, would you use this service?” Pos-
sible responses were, “yes”, “no”, and “don’t know/re-
fuse”. Then, we examined the acceptability of a SIF
service among the participants who reported they would
use the service. These questions included how often one
would use a SIF (once or a couple times, about once a
month, at least every week, every day), the longest time
willing to travel to a SIF (1–5, 6–10, 11–20, 21–30 min,
more than 30 min), and time of the day most likely to
use a SIF (8 a.m.–12 p.m., 12 p.m.–4 p.m., 4 p.m.–8
p.m., 8 p.m.–12 midnight). We also asked participants
who had ever injected drugs why they or their friends
have needed help injecting (new user, don’t know how,
bad veins/no veins, hate needles/afraid, too high/dope-
sick, shaky hands, other), since staff at SIFs often edu-
cate attendees on the best injection practices, so reasons
for needing help to inject might be relevant when
reporting on willingness to use a SIF. These questions
were guided by previous research exploring the accept-
ability of SIF services. We report the number and pro-
portion of participants who endorsed each answer
choice. Finally, we explored factors associated with will-
ingness to use a SIF, comparing participants who
reported they were willing to use a SIF vs. participants
who were unwilling or unsure using Fisher’s exact test
and the Wilcoxon rank sum test. The factors we
explored were age, sex at birth (male vs. female), race
(categorized as white, black, or mixed/other), Hispanic
or Latino descent, experiencing homelessness in the last
six months (defined as not having a regular place to stay,
living in a shelter because of nowhere else to go, or
Bouvier et al. Harm Reduction Journal  (2017) 14:13 Page 3 of 9
living in a place not ordinarily used for sleeping), ever
overdosing by accident, frequency of injection drug use
(≥daily vs. <daily), ever borrowing a used syringe/needle
and ever lending a used syringe/needle, respectively
(among the participants who reported a history of injec-
tion drug use), typically using prescription opioids non-
medically alone, and ever using heroin. We also ascer-
tained whether participants had used diverted fentanyl
non-medically in the preceding six months (i.e., partici-
pants were asked if they had used fentanyl in the form
of skin patches, pills, nasal sprays, intravenous (IV) fen-
tanyl, lozenges/lollipops, and/or films/tablets without
doctor’s orders or not as a doctor directed in the preced-
ing six months). Finally, we also asked participants how
often they used molly/MDMA/ecstasy, mushrooms,
GHB, ketamine, crystal methamphetamine, and cocaine
in the last six months (never, once or a couple times,
about once per month, at least every week, every day);
participants were considered to have engaged in opioid
and non-opioid illicit poly-substance use at least once
per month in the last six months if they reported that
they used at least one of these substances at least once
per month. These variables were guided by previous
research on willingness to use a SIF and by previous
research on risk factors for overdose. All analyses were
conducted in SAS version 9.3, and all p values were two-
sided. P values less than 0.05 were considered significant.
Results
Characteristics of participants
Among the 54 eligible participants, the median age was
26 (IQR = 24–28) and 38 (70.4%) were male. The major-
ity (74.1%) was white, 7.4% were black, and 14.8% were
mixed, bi-racial, multi-racial, or reported “Other”. Six
participants (11.1%) reported Hispanic or Latino descent.
Over one quarter (27.8%, n = 15) had been homeless in
the preceding six months. Among the 34 participants who
had ever injected drugs, 52.9% (n = 18) had ever borrowed
a used syringe/needle and 52.9% (n = 18) had ever lent a
used syringe/needle. Other sociodemographic characteris-
tics of the study sample are shown in Table 1. A compari-
son of the characteristics of the eligible sample vs. those
who were excluded is shown in the Additional file 1.
Eligible participants were more likely to be younger
(median age 26 vs. 24, p = 0.003), be white (74.1 vs.
56.8%, p = 0.034), and have accidentally overdosed (38.9
vs. 21.9%, p = 0.019).
Risk factors for overdose were prevalent: for example,
a majority (81.5%) reported using prescription opioids
non-medically alone, 66.7% had ever used heroin, and
37.0% had ever used diverted fentanyl non-medically.
Twenty-one (38.9%) participants had ever accidentally
overdosed, 11 (52.4%) of whom had accidentally over-
dosed in the last six months.
Prevalence and correlates of willingness to use a
supervised injection facility
When asked if they would use a SIF service, 63.0% (n = 34)
answered “Yes”, 31.5% (n = 17) answered “No”, and 5.6%
(n = 3) were unsure. A majority (74.1%, n = 40) thought
their friends or other people they knew would use a SIF.
Among the participants who reported willingness to use a
SIF (n = 34), the most commonly endorsed answer for how
often he/she would use a SIF was “every day” (38.2%, n =
13), and the second most commonly endorsed answer was
“at least every week” (26.5%, n = 9). The most commonly
endorsed answer for time most likely to use the service
was 8 a.m.–12 p.m. (61.8%, n = 21), and the second most
commonly endorsed answer was 12 p.m.–4 p.m. (35.3%, n
= 12). The most commonly endorsed answer for why
participants or participants’ friends have needed help inject-
ing was “Bad veins/no veins.” Among the participants who
were willing to use a SIF, 31 (91.2%) stated that their friends
would also be willing to use this service. The responses to
other acceptability questions are shown in Table 2.
Willingness to use a SIF increased with frequency of
injection drug use: two of the three (66.7%) participants
who had ever injected but not in the last six months re-
ported willingness, and 15 of the 19 (78.9%) participants
who injected less than daily in the last six months re-
ported willingness, while all 12 (100.0%) of the partici-
pants who injected daily or multiple times a day in the
last six months reported willingness. Overall, 27 (87.1%)
of the 31 participants who had injected drugs in the last
six months reported willingness. A total of five (25.0%)
of the 20 participants who had never injected drugs (but
who had a sex partner or close friend who injects) re-
ported willingness to use a SIF.
As shown in Table 1, compared to participants who
were unwilling or were unsure, participants who re-
ported willingness to use a SIF were more likely to have
been homeless in the preceding six months (41.2 vs.
5.0%, p = 0.004), have ever accidentally overdosed (50.0
vs. 20.0%, p = 0.043), report daily injection drug use
(35.3 vs. 0.0%, p < 0.001), have ever used heroin (85.3 vs.
35.0%, p < 0.001), have ever used diverted fentanyl non-
medically (50.0 vs. 15.0%, p = 0.018), and typically use
prescription opioids alone (91.2 vs. 65.0%, p = 0.028).
Discussion
Our study confirms the findings of other studies that
have reported a high prevalence of willingness to use a
SIF among people who inject drugs [37–42, 45, 46]. Be-
cause we included participants who had never injected
drugs but were at high risk of initiating injection drug
use in our analysis, we note that the overall willingness
may be lower than that reported by other studies. It is
also important to note that our sample is different from
other studies that have explored willingness to use a SIF:
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Table 1 Factors associated with willingness to use a SIF among young adult non-medical prescription opioid users in Rhode Island
Total Yes No or unsure p value
n (%) n (%) n (%)
n = 54 n = 34 n = 20
Age (median, IQR) 26 (24–28) 26.5 (24–28) 25 (22.5–28) 0.31
Sex at birth
Male 38 (70.4) 24 (70.6) 14 (70.0) 1.00
Female 16 (29.6) 10 (29.4) 6 (30.0)
Race
Black, African, Haitian, or Cape Verdean 4 (7.4) 1 (2.9) 3 (15.0) 0.16
White 40 (74.1) 27 (79.4) 13 (65.0)
Aggregated “Mixed/Other” 8 (14.8) 4 (11.8) 4 (20.0)
Ethnicity
Not Hispanic or Latino 48 (88.9) 29 (85.3) 19 (95.0) 0.39
Hispanic or Latino 6 (11.1) 5 (14.7) 1 (5.0)
Been homeless in the last six months
Yes 15 (27.8) 14 (41.2) 1 (5.0) <0.01
No 39 (72.2) 20 (58.8) 19 (95.0)
Ever overdosed by accident
Yes 21 (38.9) 17 (50.0) 4 (20.0) 0.04
No 33 (61.1) 17 (50.0) 16 (80.0)
Daily injection drug use
Yes 12 (22.2) 12 (35.3) 0 (0.0) <0.01
Noa 42 (77.8) 22 (64.7) 20 (100.0)
Ever borrowed a used syringe/needleb
Yes 18 (52.9) 16 (57.1) 2 (40.0) 0.64
No 15 (44.1) 12 (42.9) 3 (60.0)
Ever lent a used syringe/needleb
Yes 18 (52.9) 17 (60.7) 1 (20.0) 0.15
No 15 (44.1) 11 (39.3) 4 (80.0)
Typically use prescription opioids non-medically alone
Yes 44 (81.5) 31 (91.2) 13 (65.0) 0.03
No 10 (18.5) 3 (8.8) 7 (35.0)
Ever used heroin
Yes 36 (66.7) 29 (85.3) 7 (35.0) <0.01
No 18 (33.3) 5 (14.7) 13 (65.0)
Ever used diverted fentanyl non-medically
Yes 20 (37.0) 17 (50.0) 3 (15.0) 0.02
No 34 (63.0) 17 (50.0) 17 (85.0)
Illicit poly-substance use at least once per month
in the last six months
Yes 28 (51.9) 20 (58.8) 8 (40.0) 0.26
No 26 (48.1) 14 (41.2) 12 (60.0)
aCategory includes 19 participants who injected in the last six months but less than daily, 3 participants who reported lifetime injection drug use but none in the
last six months, and 20 participants who reported no lifetime injection drug use (but were considered to be at high risk of initiating injection drug use)
bAmong the 34 participants who had ever injected drugs
c Not all columns add to 100% due to missing values
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whereas previous studies have recruited people who in-
ject drugs, the sample for this analysis is comprised of
people who reported past 30-day NMPO use and who
inject drugs or have a sex partner or close friend who in-
jects drugs.
Our analyses support previous research on the corre-
lates of SIF acceptability by confirming that variables
such as having used heroin and having accidentally over-
dosed are associated with higher acceptability [37–40,
45, 46]. We also observed correlates of willingness we
believe have not yet been identified. Notably, of those
willing, 50% reported ever using diverted fentanyl non-
medically. This finding demonstrates that SIFs may be
an effective approach to reduce the high rate of
fentanyl-attributable fatal overdoses observed in Rhode
Island and in other regions throughout the USA [54,
55]. For decades, United States drug policy has focused
on combating drug trafficking, yet illicit drug prices have
decreased, rates of drug use (specifically heroin use) are
increasing, and overdose mortality rates are at an all-
time high [26, 36]. Further exacerbating overdose risk is
the increasing presence of potent contaminants (notably
fentanyl) in heroin, counterfeit pills, and other drugs
[32, 56, 57]. In this context, it is very unlikely that con-
tinuing to pursue “supply side” interventions and zero
tolerance/abstinence-based policies will address this
public health issue in an effective way [36, 58]. Rather,
robust harm reduction programming and increased
access to evidence-based treatment services are more
paramount than ever to address the rising incidence of
fentanyl-attributable overdose deaths [32, 59].
It has been proposed that there are various strategies
involving local and state law to launch a SIF, but such a
facility could only proceed free of legal uncertainty with
federal authorities’ explicit authorization or decision to
not interfere [60–62]. Nonetheless, efforts to open a SIF
have been launched in multiple US cities, including San
Francisco, Seattle, New York City, Baltimore, and Ithaca,
New York [63–66]. A nonprofit organization in Boston
recently established a supervised environment in which
people can be medically monitored after using street
drugs but cannot use drugs on the premises [67]. The
New York City Council recently allocated $100,000 to
the New York City health department to study the feasi-
bility and impact of a SIF in the city [68]. Our results
further demonstrate that efforts to establish a SIF in the
USA are supported by a growing body of scientific
evidence, and that persons at high risk of overdose
would likely be willing to use such a facility.
Our study has important limitations that should be
considered when interpreting our findings. First, our
pilot study had a small sample size (n = 54) and thus
limited statistical power. Because of this small sample
size, we were not able to conduct any multivariate
analyses; thus, observed associations may be con-
founded. Larger studies are needed to identify the inde-
pendent characteristics associated with higher
willingness to use a SIF. Second, only 54 of the 200
RAPiDS participants were asked questions regarding
willingness to use a SIF and met our eligibility criteria.
Eligible participants were more likely to be younger, be
white, have ever been homeless, have been incarcerated,
and have accidentally overdosed. It is possible that our
sample is not representative of the full study in other
important ways. Although we used multiple strategies to
recruit participants, it is possible our findings may not
Table 2 Acceptability of a SIF service among participants who
reported willingness to use a SIF (n = 34)
n (%)
How often would you use a SIF?
Once or a couple of times 8 (23.5)
About once a month 3 (8.8)
At least every week 9 (26.5)
Every day 13 (38.2)
Don’t know 1 (2.9)
Longest time willing to travel to a SIF
1–10 min 6 (17.7)
11–20 min 12 (35.3)
21–30 min 8 (23.5)
More than 30 min 6 (17.7)
Don’t know 2 (5.9)
When would you be most likely to use a SIF?a
Mornings, like 8 a.m.–12 p.m. 21 (61.8)
Afternoons, like 12 p.m.–4 p.m. 12 (35.3)
Evenings, like 4 p.m.–8 p.m. 10 (29.4)
Late evenings, like 8 p.m.–12 midnight 7 (20.6)
Why have you or your friends needed help
injecting?b
New user 13 (46.4)
Don’t know how 15 (53.6)
Bad veins/no veins 18 (64.3)
Hate needles/afraid 6 (21.4)
Too high/dopesick 9 (32.1)
Shaky hands 7 (25.0)
Other 3 (10.7)
Do you think that your friends (or other people
you know) would use this service?
Yes 31 (91.2)
No 2 (5.9)
Don’t know 1 (2.9)
aColumn adds to >34 because this question was “check all that apply”
bAmong the 28 participants who had ever injected drugs. Column adds to >28
because this question was “check all that apply”
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be generalizable to all young adults who use prescription
opioids non-medically in Rhode Island. Third, the age
range of our participants (18–29) is small, especially
considering the aging of people who inject drugs in the
USA [69]. In addition, the primary goal of our study was
to recruit people who reported NMPO use, whereas
other populations of people who inject drugs might use
a SIF. These eligibility criteria thus reduce the
generalizability of our study to all people in Rhode
Island who might use a SIF. Fourth, our survey asked if
participants would use a hypothetical facility where
people could inject drugs but did not ascertain whether
participants had heard about SIFs before the survey.
Additionally, participants were not asked why they were
willing or not willing to use such a facility or to explain
their responses to questions about preferences of a
hypothetical SIF service. For example, our finding that
mornings (8 a.m.–12 p.m.) and afternoons (12 p.m.–4
p.m.) were the most commonly endorsed answer choices
for times most likely to use a SIF contradicts previous
qualitative research that has reported that people use
SIFs more often later in the day [70]. It is possible that
some participants only use opioids once daily in the
morning to get through the day and/or to avoid with-
drawal symptoms. More research is required to further
explore willingness to use a SIF and participant prefer-
ences of a potential SIF service. Furthermore, our survey
asked specifically about a facility where people could in-
ject drugs; additional studies are needed to further
explore willingness to use a supervised consumption
facility for non-injection drug use among individuals
who do not inject drugs but are at high risk of overdose,
including those who use diverted fentanyl non-medically
[11, 53]. Finally, we relied on self-reported willingness to
use a hypothetical SIF service. While it has been found
that reported willingness measures collected before SIF
opening independently predicted later attendance [71], it
is important to note the potential invalidity of reporting
willingness to use a hypothetical SIF.
Conclusions
In summary, this study represents an early step in
exploring the feasibility of implementing a SIF in the
state of Rhode Island. If a SIF were opened, more than
six in ten of our study participants reported they would
use the service, and more than eight in ten of partici-
pants who have injected drugs reported they would use
the service. Established risk factors for overdose were
associated with higher SIF acceptability, indicating that
young people at the highest risk of overdose might
ultimately be the same individuals to use the facility. We
also identified novel factors associated with higher will-
ingness to use a SIF, including use of diverted fentanyl
non-medically. Among the participants who reported
willingness to use a SIF, the majority stated they would
use the facility at least once a week. These data indicate
that SIFs merit consideration to reduce overdose mortal-
ity among young adults who use prescription opioids
non-medically and who inject drugs or are at risk of ini-
tiating injection drug use in the USA.
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